News & Updates
Filter by Specialty:
Bimekizumab triumphs in bDMARD-naïve psoriatic arthritis patients
Patients with psoriatic arthritis (PsA) with no prior exposure to biological disease-modifying antirheumatic drugs (bDMARDs) experience improvements in their condition when treated with bimekizumab, according to results of the phase III BE OPTIMAL trial.
Bimekizumab triumphs in bDMARD-naïve psoriatic arthritis patients
20 Jun 2022
Insulin resistance tied to atherogenic lipoprotein/lipid, cIMT in obese youths
Insulin resistance in young people with obesity is positively associated with an atherogenic lipoprotein/lipid profile and carotid intima-media thickness (cIMT), regardless of their glucose tolerance status, suggests a study.
Insulin resistance tied to atherogenic lipoprotein/lipid, cIMT in obese youths
20 Jun 2022
Vunakizumab safe, effective in moderate-to-severe plaque psoriasis
Treatment with vunakizumab, a novel interleukin 17A monoclonal antibody, shows promise for moderate-to-severe plaque psoriasis and good tolerability, according to the results of a recent study.
Vunakizumab safe, effective in moderate-to-severe plaque psoriasis
20 Jun 2022
Antibiotic use for chronic endometritis poses risk of miscarriage after ART
The use of antibiotic therapy to resolve chronic endometritis can put women undergoing assisted reproductive treatment (ART) at heightened risk of pregnancy loss, according to a study.